Can diverse tissue samples unlock Obesity's secrets?

NCT ID NCT03022682

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

Researchers are building a large, diverse group of adults with varying body sizes, ethnicities, and diabetes risk. They will collect blood, stool, and fat tissue samples to study how obesity relates to diabetes and other health issues. The goal is to create a rich resource for future research into obesity's causes and consequences.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This study could uncover biological markers in blood, stool, and fat tissue that explain why obesity leads to diabetes, potentially guiding future treatments.
What could go wrong
This is an observational study, not a treatment test. It may not produce immediate clinical benefits, and findings might not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Feb 2015

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

IDEO Cohort participants

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants will be healthy individuals between the ages of 18-75 years. These cutoffs are designed to allow inclusion of postmenopausal women, and younger/more active patients who are increasingly undergoing bariatric surgery. * Patients with either diabetes type 2 or the metabolic syndrome will be included in the cohort. Exclusion Criteria: * Participants with chronic kidney disease (\> stage 4) * Autoimmune/inflammatory disease (e.g., Lupus, Ulcerative Colitis, etc.) * Unstable angina, New York (NY) class III or IV congestive heart failure or myocardial infarction within 3 months of entry * Clinically significant liver disease (e.g. Cirrhosis or liver failure) * Weight \> 450 pounds (DXA scan weight limit) * History of organ transplant * Treatment with chemotherapy or radiation therapy at the time of enrollment in study. * Poorly controlled asthma (participants requiring inhaled glucocorticoids and/or oral glucocorticoids) * Current nasal corticosteroid use (within the past month) * Excessive alcohol or substance abuse * Current use of anabolic steroids or testosterone for bodybuilding purposes. Testosterone use is permitted if prescribed for hypogonadism and dose stable for the past 6 months. * Patients actively enrolled in interventional trials involving investigational agents * Pregnant or breast-feeding women * Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee. * History of abnormal clotting * Previous bariatric surgery * Anticoagulant use * Methadone medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.